Next-gen cancer meds spur pricing concerns; Pfizer, Kyowa team up on oncology combo;

@FierceBiotech: Did you miss our list of notable academic-pharma alliances of 2014? Check it out here | Follow @FierceBiotech

@JohnCFierce: Baxter inks a big lease in the heart of Cambridge for biopharma R&D headquarters - (more for hubs, less for Chicago). Article | Follow @JohnCFierce

@DamianFierce: buying antiviral outfit Alios for $1.75B in cash(!). Press release | Follow @DamianFierce

@EmilyMFierce: New class of antibiotics could fight drug-resistant tuberculosis. FierceBiotech Research story | Follow @EmilyMFierce

> The latest generation of cancer treatments has wowed physicians and analysts at Spain's European Society for Medical Oncology, but looming concerns over pricing have elbowed their way into all the talk about safety and efficacy. Story

> Pfizer ($PFE) has signed a deal with Kyowa Hakko Kirin to pair its own PF-05082566 with the Japanese company's mogamulizumab, testing the two cancer drugs in a Phase Ib clinical trial in patients with solid tumors. News

> Sarepta Therapeutics ($SRPT) is touting positive Phase I results for AVI-7100, an early-stage treatment for influenza. More

Medical Device News

@FierceMedDev: ICYMI yesterday: Activist investor intensifies pressure on Volcano. Article | Follow @FierceMedDev

@MichaelGFierce: Purdue team recreates tumor microenvironment to study nanomed delivery. FierceDrugDelivery story | Follow @MichaelGFierce

@VarunSaxena2: Interesting tidbit about off-label use: biliary stents have been used for cardiac indications in the past, panelists say. | Follow @VarunSaxena2

@EmilyWFierce: Closed-loop epidural stimulation system helped paralyzed rats take 1,000 steps and navigate "rodent-sized stairs." More from MIT Technology Review | Follow @EmilyWFierce

> Study: Publicly available information about 510(k) devices' safety and effectiveness lacking. Article

> Israeli devicemaker eyes lucrative sleep disorder market. Story

> Microsoft, Aerocrine partner to send asthma device data to the cloud. Report

Pharma News

@FiercePharma: ICYMI: This week's issue of FierceAnimalHealth. Subscribe here to get it every week. | Follow @FiercePharma

@TracyStaton: ICYMI yesterday: Bristol-Myers' oncology star lines up for lung cancer approval, leading the PD-1 pack. Story from FierceBiotech | Follow @TracyStaton

@CarlyHFierce: Once-rejected drugs in Gilead's Stribild get FDA nod to go it alone. Story | Follow @CarlyHFierce

> Salix's Relistor has its chance to get a jump on AZ's new constipation med. Report

> Allergan's next tug-of-war move: Attack Valeant's rosy Q3 forecast. Story

> AbbVie to employees: We're definitely merging with Shire, new tax rules aside. More

Biotech Research News

> New class of antibiotics could fight drug-resistant tuberculosis. More

> Protein 'map' points way to combating chemo-resistant cancer. Report

> Scientists replicate ALS dementia in mice. Item

> Hemispherx to test FDA-rejected drug, other candidates against Ebola. Article

> Monkey study reveals clues for HIV eradication. Story

Pharma Manufacturing News

> Report: Indian government to take legal action over drug quality paper. Item

> Apotex tries to 'set the record straight' after Health Canada quarantine request. More

> FDA warns of contaminated Chinese meds after toddler suffers lead poisoning. Article

> Strides and Shasun plan merger to create big, 'de-risking' production network. Story

> Credit Suisse: FDA 483 unlikely to lead to import alert for Sun. Report

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

City of Hope and Canadian biotech Biovaxys Technology reported positive animal data for their COVID vaccines that could offer alternatives to mRNA.

4D is adding a trio of executives to spearhead its work in heart, eye and lung diseases as it pushes programs into and through the clinic.

Janssen has sent off its mutation-specific non-small cell lung cancer drug amivantamab to the FDA.